Improving the manufacturing of cell therapies for cancer treatment.
Official title: SBIR PHASE II, TOPIC 429: A NEW PARADIGM FOR AUTOLOGOUS AND ALLOGENEIC CELL THERAPY MANUFACTURING
Funded at Proteios Technology, INC. · NIH-10976161 · Data updated 2026-11-12
This study is working on a new way to make cancer treatments using your own cells or donated cells, with the goal of making these therapies easier and faster to produce so more patients can get the help they need.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Proteios Technology, INC. NIH-funded |
| Lab location | 1 site (Issaquah, United States) |
| Project start | September 15, 2023 |
| Project end | September 14, 2025 |
| Funding year | 2023 |
| Award (this year) | $1,049,979 |
| NIH project number | 75N91023C00028-0-9999-1 |
| Project ID | NIH-10976161 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with cancer who may benefit from autologous or allogeneic cell therapies.
✕Less likely to help
Patients who do not have cancer or are not eligible for cell-based therapies may not receive any benefit from this research.
What this research studies
This research focuses on developing a new manufacturing system for autologous and allogeneic cell therapies, which are promising treatments for cancer. The approach aims to create a fully-automated system that can process multiple cell therapies simultaneously, significantly increasing the availability of these treatments. By isolating, activating, genetically modifying, expanding, and formulating cell-based therapies in a controlled environment, the project seeks to reduce the time and cost associated with current manufacturing methods. Ultimately, this innovation aims to make cell-based therapies more accessible to patients by allowing for point-of-care applications.
Why it matters
Potential benefit: If successful, this research could make advanced cell-based therapies more widely available and affordable for cancer patients.
How similar studies have gone: Other research has shown promise in automating cell therapy manufacturing, indicating that this approach could lead to significant advancements in the field.
Where this research is happening
-
Proteios Technology, INC.
Issaquah, United States Active
Researchers
- Principal investigator: Snyder, Bob — Proteios Technology, INC.
- Study coordinator: Snyder, Bob
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.